ProQR Therapeutics Past Earnings Performance
Past criteria checks 0/6
ProQR Therapeutics has been growing earnings at an average annual rate of 9.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 51.2% per year.
Key information
9.9%
Earnings growth rate
23.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 51.2% |
Return on equity | -95.8% |
Net Margin | -130.2% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump
Oct 23ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01Revenue & Expenses Breakdown
How ProQR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 18 | -24 | 14 | 33 |
30 Jun 24 | 16 | -22 | 15 | 30 |
31 Mar 24 | 11 | -27 | 16 | 28 |
31 Dec 23 | 7 | -28 | 16 | 25 |
30 Sep 23 | 5 | -36 | 14 | 28 |
30 Jun 23 | 4 | -54 | 17 | 38 |
31 Mar 23 | 4 | -59 | 18 | 44 |
31 Dec 22 | 4 | -64 | 19 | 51 |
30 Sep 22 | 4 | -69 | 21 | 53 |
30 Jun 22 | 4 | -61 | 20 | 48 |
31 Mar 22 | 3 | -63 | 19 | 47 |
31 Dec 21 | 2 | -61 | 17 | 42 |
30 Sep 21 | 2 | -57 | 16 | 38 |
30 Jun 21 | 2 | -55 | 14 | 35 |
31 Mar 21 | 1 | -43 | 13 | 34 |
31 Dec 20 | 1 | -47 | 14 | 38 |
30 Sep 20 | 1 | -52 | 14 | 44 |
30 Jun 20 | 1 | -51 | 14 | 46 |
31 Mar 20 | 2 | -58 | 14 | 47 |
31 Dec 19 | 2 | -56 | 13 | 46 |
30 Sep 19 | 3 | -51 | 14 | 42 |
30 Jun 19 | 5 | -45 | 13 | 37 |
31 Mar 19 | 6 | -40 | 13 | 34 |
31 Dec 18 | 6 | -37 | 13 | 30 |
30 Sep 18 | 4 | -35 | 11 | 28 |
30 Jun 18 | 2 | -40 | 11 | 29 |
31 Mar 18 | 1 | -44 | 11 | 31 |
31 Dec 17 | 1 | -44 | 11 | 31 |
30 Sep 17 | 1 | -41 | 10 | 31 |
30 Jun 17 | 1 | -41 | 9 | 32 |
31 Mar 17 | 1 | -39 | 9 | 33 |
31 Dec 16 | 2 | -39 | 9 | 32 |
30 Sep 16 | 3 | -36 | 9 | 30 |
30 Jun 16 | 3 | -33 | 9 | 28 |
31 Mar 16 | 3 | -31 | 8 | 25 |
31 Dec 15 | 3 | -21 | 7 | 23 |
30 Sep 15 | 3 | -17 | 7 | 20 |
30 Jun 15 | 1 | -14 | 8 | 17 |
31 Mar 15 | 1 | -10 | 8 | 14 |
31 Dec 14 | 0 | -12 | 7 | 10 |
30 Sep 14 | 0 | -12 | 5 | 8 |
30 Jun 14 | 0 | -9 | 3 | 6 |
31 Mar 14 | 0 | -5 | 1 | 4 |
31 Dec 13 | 0 | -3 | 1 | 3 |
Quality Earnings: PRQR is currently unprofitable.
Growing Profit Margin: PRQR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRQR is unprofitable, but has reduced losses over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare PRQR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRQR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PRQR has a negative Return on Equity (-95.83%), as it is currently unprofitable.